Gland Pharma Limited (NSE: GLAND) shares were trading around \u20b91,688, up about 0.8% in early Wednesday deals, after the Hyderabad-based injectables maker reported its third-quarter results. The stock trades well below its 52-week high of \u20b92,131 and above its 52-week low near \u20b91,278, reflecting a sideways to slightly softer trend over the past year.<\/p>\n\n\n\n
Gland Pharma posted consolidated revenue of \u20b916,954 million for the quarter ended Dec. 31, 2025 (Q3 FY26), a 22% year-on-year increase from \u20b913,841 million in Q3 FY25. Gross profit rose 21% to \u20b911,187 million, with gross margin at 66% versus 67% a year earlier. EBITDA increased 21% to \u20b94,349 million, with margin steady at 26%. Adjusted EBITDA climbed 25% and maintained a 26% margin. Adjusted profit after tax grew 37% to \u20b92,797 million, with an adj. PAT margin of 16% versus 15% in Q3 FY25. Nine-month revenue rose 12% to \u20b946,879 million and adj. PAT was up 33% year-on-year.<\/p>\n\n\n\n
Revenue in the U.S. market increased 19% year-on-year, while Europe reported a 54% rise. India sales grew 32%, with modest gains in other regions. R&D expenses for the quarter were \u20b9650 million, reflecting increased product filings and development activity. The company launched nine molecules in the U.S. and filed multiple ANDAs during the quarter.<\/p>\n\n\n\n
Gland Pharma delivered double-digit revenue growth both quarterly and for the nine-month period, with margins largely stable. The year-to-date figures indicate consistent expansion versus the prior fiscal period. Gross and adjusted profit metrics improved in absolute terms, while margin percentages remained largely similar to last year\u2019s levels.<\/p>\n\n\n\n
There were no widely reported analyst upgrades, downgrades or price-target changes linked directly to today\u2019s Q3 FY26 results. Previous analyst actions around the stock have occurred in prior quarters but none were disclosed in the latest session.<\/p>\n\n\n\n
Over the past 12 months, Gland Pharma\u2019s share price has fluctuated within a broad range of about \u20b91,278 to \u20b92,131, reflecting volatility around earnings and broader sector movements.<\/p>\n","protected":false},"excerpt":{"rendered":"
Gland Pharma Limited (NSE: GLAND) shares were trading around \u20b91,688, up about 0.8% in early Wednesday deals, after the Hyderabad-based injectables maker reported its third-quarter results. The stock trades well below its 52-week high of \u20b92,131 and above its 52-week low near \u20b91,278, reflecting a sideways to slightly softer trend over the past year. Quarterly […]<\/p>\n","protected":false},"author":2384,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392,5747],"tags":[8157,9039],"class_list":["post-178238","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","category-healthcare-stocks","tag-healthcare","tag-specialty-generics"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":178326,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q3-fy26-earnings-results\/","url_meta":{"origin":178238,"position":0},"title":"Gland Pharma Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 29, 2026","format":false,"excerpt":"Executive Summary Gland Pharma Ltd reported Q3FY26 revenues of \u20b91,695 crore, up 22.47% YoY, with consolidated net profit rising 27.32% to \u20b9261 crore. Total expenses increased 20.03% YoY to \u20b91,372 crore, reflecting strong revenue growth with controlled cost escalation. Revenue & Growth Revenues grew to \u20b91,695.00 crore in Q3FY26 from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170073,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q1-fy26-earnings-results\/","url_meta":{"origin":178238,"position":1},"title":"Gland Pharma Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 12, 2025","format":false,"excerpt":"Gland Pharma Limited, established in Hyderabad, India in 1978, has evolved from being a contract manufacturer of small-volume liquid parenteral products to becoming one of the largest and fastest-growing injectable-focused companies in the world. With a presence in over 60 countries\u2014including the United States, Europe, Canada, Australia, and India\u2014the company\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"GLAND Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172096,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":178238,"position":2},"title":"Gland Pharma\u00a0Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 4, 2025","format":false,"excerpt":"Gland Pharma, a Hyderabad-based global injectable-focused pharma company, reported steady financial growth in Q2 FY26 with strong performance in key international markets. Financial Highlights: Revenues increased 5.76% year on year to \u20b91,487 crore from \u20b91,406 crore. Total expenses rose 6.45% to \u20b91,287 crore from \u20b91,209 crore. Consolidated net profit rose\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":140762,"url":"https:\/\/alphastreet.com\/india\/gland-pharmas-acquisition-of-cenexi-decline-in-lead-products-market-share\/","url_meta":{"origin":178238,"position":3},"title":"Gland Pharma\u2019s Acquisition Of Cenexi & Decline In Lead Product\u2019s Market Share","author":"Hardik Bhandare","date":"February 9, 2023","format":false,"excerpt":"Gland Pharma Limited (NSE: GLAND) is a major player in the Indian pharmaceutical market, specialising in the production and sale of generic injectable pharmaceuticals. It was founded in 1978 and went public in November 2020. The company's products are used in a wide range of therapeutic areas, including oncology, critical\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":140768,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-gland-pharma-for-q3-fy23\/","url_meta":{"origin":178238,"position":4},"title":"Earnings Summary Of Gland Pharma For Q3 FY23","author":"Hardik Bhandare","date":"February 9, 2023","format":false,"excerpt":"Gland Pharma Limited (NSE: GLAND) is an Indian pharmaceutical company that specialises in producing high-quality, low-cost generic medications. The company has a broad range of products and is expanding its presence in both domestic and foreign markets. In terms of earnings, Revenue from Operations for Q3 FY23 was \u20b9938.28 crore,\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":138943,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-q3-fy23-net-profit-down-to-232-crore\/","url_meta":{"origin":178238,"position":5},"title":"Gland Pharma Limited Q3 FY23; Net Profit Down To 232 Crore","author":"Hardik Bhandare","date":"January 23, 2023","format":false,"excerpt":"Gland Pharma Limited (NSE: GLAND) reported Revenue from Operations of \u20b9938.28 Crore down from \u20b91,063.32 Crore year on year, a decline of 11.8%. Consolidated Net Profit of \u20b9231.94 Crore, slumped 15% from \u20b9273 Crore in the same quarter of the previous year. The Earnings per Share is \u20b914.08 for this\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2384"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=178238"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178238\/revisions"}],"predecessor-version":[{"id":178239,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178238\/revisions\/178239"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=178238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=178238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=178238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}